Mayo Clinic Proceedings and Steatohepatitis: From NASH Recognition to MASH Therapy.
作者信息
Erickson Hanna L, Viggiano Thomas R, Malhi Harmeet
机构信息
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
出版信息
Mayo Clin Proc. 2025 May 7. doi: 10.1016/j.mayocp.2025.03.030.
Abstract
摘要
相似文献
1
Mayo Clinic Proceedings and Steatohepatitis: From NASH Recognition to MASH Therapy.《梅奥诊所学报》与脂肪性肝炎：从非酒精性脂肪性肝炎的认识到代谢相关脂肪性肝炎的治疗
Mayo Clin Proc. 2025 May 7. doi: 10.1016/j.mayocp.2025.03.030.
2
NASH-CHECK patient-reported outcome instrument: evaluation of content and face validity for patients with metabolic dysfunction-associated steatohepatitis and compensated cirrhosis.NASH-CHECK患者报告结局量表：对代谢功能障碍相关脂肪性肝炎和代偿期肝硬化患者的内容效度和表面效度评估
J Patient Rep Outcomes. 2025 Jul 1;9(1):76. doi: 10.1186/s41687-025-00881-6.
3
How improvements in US FDA regulatory process and procedures led to the drug approval for first ever treatment of a common liver disease.美国食品药品监督管理局（FDA）监管流程和程序的改进如何促成了有史以来第一种常见肝脏疾病治疗药物的获批。
Acta Pharmacol Sin. 2025 Mar;46(3):515-524. doi: 10.1038/s41401-024-01396-4. Epub 2024 Nov 7.
4
Resolution of Metabolic Dysfunction-associated Steatohepatitis With No Worsening of Fibrosis After Bariatric Surgery Improves 15-year Survival: A Prospective Cohort Study.减重手术后代谢功能障碍相关脂肪性肝炎的缓解且纤维化无恶化可改善15年生存率：一项前瞻性队列研究
Clin Gastroenterol Hepatol. 2024 Dec 19. doi: 10.1016/j.cgh.2024.10.025.
5
Metabolic Dysfunction-Associated Steatohepatitis Diagnosis and Management in Germany: Insights From an Expert Consensus Panel.德国代谢功能障碍相关脂肪性肝炎的诊断与管理：专家共识小组的见解
Liver Int. 2025 Aug;45(8):e70225. doi: 10.1111/liv.70225.
6
Consistent improvements in liver histology across subgroups in a post hoc analysis of the SYNERGY-NASH trial with tirzepatide.在使用替尔泊肽的SYNERGY-NASH试验的事后分析中，各亚组的肝脏组织学均持续改善。
JHEP Rep. 2025 Jun 6;7(8):101472. doi: 10.1016/j.jhepr.2025.101472. eCollection 2025 Aug.
7
Molecular spectroscopy of blood plasma differentiates metabolic dysfunction-associated steatohepatitis from steatosis.血浆分子光谱法可区分代谢功能障碍相关脂肪性肝炎与单纯性脂肪肝。
J Transl Med. 2025 Aug 6;23(1):868. doi: 10.1186/s12967-025-06885-6.
8
Endoscopic Sleeve Gastroplasty Plus Lifestyle Intervention in Patients With Metabolic Dysfunction-associated Steatohepatitis: A Multicenter, Sham-controlled, Randomized Trial.内镜下袖状胃成形术联合生活方式干预治疗代谢功能障碍相关脂肪性肝炎患者：一项多中心、假手术对照、随机试验
Clin Gastroenterol Hepatol. 2025 Aug;23(9):1556-1566.e3. doi: 10.1016/j.cgh.2024.10.027. Epub 2024 Dec 16.
9
Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis.代谢相关脂肪性肝炎中衰老肝星状细胞的表型和个体发生。
J Hepatol. 2024 Aug;81(2):207-217. doi: 10.1016/j.jhep.2024.03.014. Epub 2024 Mar 18.
10
Glycogen synthase kinase 3 activity enhances liver inflammation in MASH.糖原合酶激酶3活性增强了非酒精性脂肪性肝炎中的肝脏炎症。
JHEP Rep. 2024 Mar 26;6(6):101073. doi: 10.1016/j.jhepr.2024.101073. eCollection 2024 Jun.
本文引用的文献
1
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
2
National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.采用共识命名法的脂肪肝疾病及其分类的全国流行率估计。
Hepatology. 2024 Mar 1;79(3):666-673. doi: 10.1097/HEP.0000000000000604. Epub 2023 Sep 20.
3
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家共识：新的非酒精性脂肪性肝病命名。
Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24.
4
Magnetic resonance elastography: from invention to standard of care.磁共振弹性成像：从发明到临床常规应用。
Abdom Radiol (NY). 2022 Sep;47(9):3028-3036. doi: 10.1007/s00261-022-03597-z. Epub 2022 Jul 19.
5
Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design.非酒精性脂肪性肝病的临床病程及其对临床试验设计的影响。
J Hepatol. 2022 Nov;77(5):1237-1245. doi: 10.1016/j.jhep.2022.07.004. Epub 2022 Jul 16.
6
Randomized placebo-controlled trial of losartan for pediatric NAFLD.随机安慰剂对照试验研究氯沙坦治疗小儿非酒精性脂肪性肝病。
Hepatology. 2022 Aug;76(2):429-444. doi: 10.1002/hep.32403. Epub 2022 Feb 28.
7
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病成人患者结局的前瞻性研究。
N Engl J Med. 2021 Oct 21;385(17):1559-1569. doi: 10.1056/NEJMoa2029349.
8
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.吡格列酮、维生素 E 或安慰剂治疗非酒精性脂肪性肝炎。
N Engl J Med. 2010 May 6;362(18):1675-85. doi: 10.1056/NEJMoa0907929. Epub 2010 Apr 28.
9
Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis.非酒精性脂肪性肝炎纤维化进展危险因素的系统评价
J Hepatol. 2009 Aug;51(2):371-9. doi: 10.1016/j.jhep.2009.03.019. Epub 2009 May 3.
10
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.PNPLA3基因变异会使人易患非酒精性脂肪性肝病。
Nat Genet. 2008 Dec;40(12):1461-5. doi: 10.1038/ng.257. Epub 2008 Sep 25.
Zotero 插件